^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | zorifertinib (AZD3759) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
Published date:
09/21/2023
Excerpt:
We initiated a phase 2, multi-center, umbrella trial (CTONG1702, NCT03574402). The eighth arm assessed the efficacy and safety of AZD3759 in untreated EGFR-mutated NSCLC with CNS metastases....Furthermore, 18 patients (60%) had an EGFR exon 19 deletion, 11 (37%) had an exon 21 L858R mutation...We summarized the clinical activity of AZD3759 in patients with an EGFR exon 19 deletion or an exon 21 L858R mutation in Supplementary Table S2...We found that 200 mg bid improved antitumor activity and decreased toxicities, which allowed more patients to benefit from AZD3759 for a longer period of time.
DOI:
https://doi.org/10.1016/j.eclinm.2023.102238
Trial ID:
